Therapeutic Efficacy to Dose-Dependent Toxicity of Cabazitaxel in C6-Induced Glioblastoma Model of Rats Publisher



Mohammadzadeh Z¹ ; Khaksari M² ; Nematollahi MH³ ; Kheirandish R⁴ ; Moslemizadeh A⁵ ; Delshad S⁴ ; Faramarz S⁶ ; Tezerji SS⁷ ; Torkashvand M⁸ ; Shahba S⁹ ; Bashiri H¹⁰ Show Affiliations
Source: Toxicology Research Published:2025

Abstract

This study was designed to adjust effective chemotherapy doses of cabazitaxel (CBZ) on cognitive behaviors, inflammatory cytokines and oxidative stress parameters, and survival rate in C6-induced GBM of rats. Male Sprague-Dawley rats bearing intra-caudate nucleus (CN) C6 inoculation were randomly divided into nine groups as follows: sham, tumor, Temozolomide (TMZ) vehicle, TMZ, CBZ vehicle, CBZ at doses of 0.5, 1, 2 and 4 mg/kg. Behavioral tests survival rate, histopathology, immunohistochemistry, oxidative stress, and inflammatory cytokines were evaluated. All drug treatments reduced the volume and number of tumor cells dose-dependently and CBZ4 was able to cause the greatest reduction. The %Survival rate of animals using CBZ1 significantly increased compared to other treatment groups. CBZ1 reduced anxiety-like behaviors and increased the balance of the animal with GBM. CBZ1 and CBZ2 groups improved C6-induced learning disabilities. Treatments could ameliorate tumor-induced dysregulation of oxidative stress. TNF-α/IL-10 decreased in the CBZ1 group compared to other treatment groups, which may indicate an improvement in inflammatory balance. Our findings demonstrate that the administration of CBZ at a dosage of 1 mg/kg exerts advantageous impacts on both the survival rate and neurocognitive performance of rats within the GBM model. However, our results showed that CBZ may have toxic effects, especially in a dose of 4 mg/kg. © 2025 The Author(s). Published by Oxford University Press. All rights reserved.